BIOLASE Reports First Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/5/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- LCI Industries names interim CEO as Jason Lippert retires
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
Biolase (BIOL) Misses Q1 EPS by 5c
May 9, 2019 4:21 PM EDTBiolase (NASDAQ: BIOL) reported Q1 EPS of ($0.23), $0.05 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $10.3 million versus the consensus estimate of $10.43 million.
For earnings history and earnings-related data on Biolase (BIOL) click here.
... More